Assembly Biosciences approved a new cash bonus plan effective January 1, 2026, aimed at rewarding employees based on performance goals, and increased CEO Jason A. Okazaki's bonus target from 60% to 65% of his base salary. This filing reports on events that occurred on March 24, 2026.